Pharmacokinetics of intranasal and intramuscular flunixin in healthy grower pigs
Journal of Veterinary Pharmacology and Therapeutics · 2024
DOI: 10.1111/jvp.13426 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Pharmacology and Therapeutics, 2024. Verfasst von Emily E Wiloch und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Health and Pathobiology, North Carolina State University, Raleigh, North Carolina, USA. Hauptthemen laut MEDLINE: Clonixin, Swine Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: USDA National Institute of Food and Agriculture, Food animal residue avoidance databank, National Institute of Food and Agriculture.
Abstract (Originalsprache)
Flunixin meglumine is a nonsteroidal anti‐inflammatory drug approved to manage pyrexia associated with swine respiratory disease. In the United States, no analgesic drugs are approved for use in swine by the FDA, although they are needed to manage painful conditions. This study evaluated the pharmacokinetics and relative bioavailability of intranasal versus intramuscular flunixin in grower pigs. Six pigs received 2.2 mg/kg flunixin either intranasally via atomizer or intramuscularly before receiving flunixin via the opposite route following a 5‐day washout period. Plasma samples were collected over 60 h and analysed using ultra‐performance liquid chromatography and tandem mass spectrometry to detect flunixin plasma concentrations. A non‐compartmental pharmacokinetic analysis was performed. The median C max was 4.0 μg/mL and 2.7 μg/mL for intramuscular and intranasal administration, respectively, while the median AUC inf was 6.9 h μg/mL for intramuscular administration and 4.9 h μg/mL for intranasal administration. For both routes, the median T max was 0.2 h, and flunixin was detectable in some samples up to 60 h post‐administration. Intranasal delivery had a relative bioavailability of 88.5%. These results suggest that intranasal flunixin has similar, although variable, pharmacokinetic parameters to the intramuscular route, making it a viable route of administration for use in grower swine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Population Health and Pathobiology, North Carolina State University, Raleigh, North Carolina, USA.
- Food Animal Residue Avoidance Databank (FARAD), North Carolina State University, Raleigh, North Carolina, USA.
- Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina, USA.
- Department of Molecular Biomedical Sciences, North Carolina State University, Raleigh, North Carolina, USA.
ORCID-Profile: Emily E Wiloch, Hiroko Enomoto, Ronald E Baynes, Kristen M Messenger
Förderung
- USDA National Institute of Food and Agriculture
- Food animal residue avoidance databank
- National Institute of Food and Agriculture
Zitieren
APA
Wiloch, E. E., Enomoto, H., Smith, L., Baynes, R. E., & Messenger, K. M. (2024). Pharmacokinetics of intranasal and intramuscular flunixin in healthy grower pigs. Journal of Veterinary Pharmacology and Therapeutics. https://doi.org/10.1111/jvp.13426
Vancouver
Wiloch EE, Enomoto H, Smith L, Baynes RE, Messenger KM. Pharmacokinetics of intranasal and intramuscular flunixin in healthy grower pigs. Journal of Veterinary Pharmacology and Therapeutics. 2024. doi:10.1111/jvp.13426
BibTeX
@article{Wiloch2024,
author = {Wiloch, Emily E and Enomoto, Hiroko and Smith, Lilly and Baynes, Ronald E and Messenger, Kristen M},
title = {Pharmacokinetics of intranasal and intramuscular flunixin in healthy grower pigs},
journal = {Journal of Veterinary Pharmacology and Therapeutics},
year = {2024},
doi = {10.1111/jvp.13426}
}
EUVIMED